These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21334602)

  • 21. Neuropsychiatric aspects of schizophrenia.
    Gur RE
    CNS Neurosci Ther; 2011 Feb; 17(1):45-51. PubMed ID: 21199445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS.
    Green MF; Butler PD; Chen Y; Geyer MA; Silverstein S; Wynn JK; Yoon JH; Zemon V
    Schizophr Bull; 2009 Jan; 35(1):163-81. PubMed ID: 19023123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring specific, rather than generalized, cognitive deficits and maximizing between-group effect size in studies of cognition and cognitive change.
    Silverstein SM
    Schizophr Bull; 2008 Jul; 34(4):645-55. PubMed ID: 18468987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting.
    Barch DM; Carter CS; Arnsten A; Buchanan RW; Cohen JD; Geyer M; Green MF; Krystal JH; Nuechterlein K; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T; Heinssen R
    Schizophr Bull; 2009 Jan; 35(1):109-14. PubMed ID: 19023126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia.
    Barch DM; Smith E
    Biol Psychiatry; 2008 Jul; 64(1):11-7. PubMed ID: 18400207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia.
    Bromley E
    Psychiatr Serv; 2007 Apr; 58(4):475-81. PubMed ID: 17412848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: Current pro-cognitive therapeutic strategies for improved pharmacological treatment in schizophrenia.
    Wadenberg ML
    Curr Pharm Des; 2014; 20(31):5045. PubMed ID: 24345264
    [No Abstract]   [Full Text] [Related]  

  • 28. CNTRICS final task selection: working memory.
    Barch DM; Berman MG; Engle R; Jones JH; Jonides J; Macdonald A; Nee DE; Redick TS; Sponheim SR
    Schizophr Bull; 2009 Jan; 35(1):136-52. PubMed ID: 18990711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia.
    Carter CS
    Schizophr Bull; 2005 Oct; 31(4):810-5. PubMed ID: 16107584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS.
    Butler PD; Chen Y; Ford JM; Geyer MA; Silverstein SM; Green MF
    Schizophr Bull; 2012 Jan; 38(1):81-91. PubMed ID: 21890745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The construct of attention in schizophrenia.
    Luck SJ; Gold JM
    Biol Psychiatry; 2008 Jul; 64(1):34-9. PubMed ID: 18374901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological cognitive enhancement in schizophrenia.
    Harvey PD
    Neuropsychol Rev; 2009 Sep; 19(3):324-35. PubMed ID: 19507034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CNTRICS final task selection: social cognitive and affective neuroscience-based measures.
    Carter CS; Barch DM; Gur R; Gur R; Pinkham A; Ochsner K
    Schizophr Bull; 2009 Jan; 35(1):153-62. PubMed ID: 19011231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. May non-antipsychotic drugs improve cognition of schizophrenia patients?
    Buoli M; Altamura AC
    Pharmacopsychiatry; 2015 Mar; 48(2):41-50. PubMed ID: 25584772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing and treating cognitive impairment in schizophrenia: current and future.
    Lin CY; Tsai GE; Lane HY
    Curr Pharm Des; 2014; 20(32):5127-38. PubMed ID: 24410565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Animal models and measures of perceptual processing in schizophrenia.
    Siegel SJ; Talpos JC; Geyer MA
    Neurosci Biobehav Rev; 2013 Nov; 37(9 Pt B):2092-8. PubMed ID: 23867801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CNTRICS final task selection: executive control.
    Barch DM; Braver TS; Carter CS; Poldrack RA; Robbins TW
    Schizophr Bull; 2009 Jan; 35(1):115-35. PubMed ID: 19011235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive [Computational] Neuroscience Test Reliability and Clinical Applications for Serious Mental Illness (CNTRaCS) Consortium: Progress and Future Directions.
    Barch DM; Boudewyn MA; Carter CC; Erickson M; Frank MJ; Gold JM; Luck SJ; MacDonald AW; Ragland JD; Ranganath C; Silverstein SM; Yonelinas A
    Curr Top Behav Neurosci; 2023; 63():19-60. PubMed ID: 36173600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verbal memory.
    Sumiyoshi T
    Handb Exp Pharmacol; 2015; 228():237-47. PubMed ID: 25977085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.